{
    "xml": "<topic id=\"PHP5950\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/lenograstim\" basename=\"lenograstim\" title=\"LENOGRASTIM\">\n<title>LENOGRASTIM</title>\n<body>\n<data name=\"vtmid\">327123007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_857996914\" title=\"Granulocyte-colony stimulating factors\">Granulocyte-colony stimulating factors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34593\" title=\"GRANULOCYTE-COLONY STIMULATING FACTORS\" namespace=\"/drug-classes/granulocyte-colony-stimulating-factors\">GRANULOCYTE-COLONY STIMULATING FACTORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<p outputclass=\"synonyms\">Recombinant human granulocyte-colony stimulating factor, rHuG-CSF</p>\n</body>\n<topic id=\"PHP61817\" outputclass=\"indicationsAndDose\" rev=\"1.36\" parent=\"/drugs/lenograstim\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only)</p>\n<p outputclass=\"therapeuticIndication\">Reduction in the duration of neutropenia and associated complications following peripheral stem cells transplantation for non-myeloid malignancy (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reduction in the duration of neutropenia and associated complications following treatment with cytotoxic-induced neutropenia associated with a significant incidence of febrile neutropenia (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion on chemotherapy.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;micrograms/kg daily for 4&#8211;6 days (5&#8211;6 days in healthy donors).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range, to be started 1&#8211;5 days after completion on chemotherapy, for timing of leucopheresis, consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61770\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/lenograstim\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Mucositis</ph>; <ph outputclass=\"sideEffect\">splenic rupture</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61939\" outputclass=\"directionsForAdministration\" rev=\"1.12\" parent=\"/drugs/lenograstim\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i>(<i>Granocyte</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; initially reconstitute with 1&#8239;mL water for injection provided (do not shake vigorously) then dilute with up to 50&#8239;mL infusion fluid for each vial of <i>Granocyte-13</i> or up to 100&#8239;mL infusion fluid for <i>Granocyte-34</i>; give over 30 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5950-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/lenograstim\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74609\" title=\"Powder and solvent for solution for injection\" namespace=\"/drugs/lenograstim/powder-and-solvent-for-solution-for-injection\">Powder and solvent for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78575\" namespace=\"/treatment-summaries/neutropenia\" title=\"Neutropenia\" count=\"1\" rel=\"backlink\">Neutropenia</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34593\" namespace=\"/drug-classes/granulocyte-colony-stimulating-factors\" title=\"GRANULOCYTE-COLONY STIMULATING FACTORS\" count=\"1\" rel=\"link\">GRANULOCYTE-COLONY STIMULATING FACTORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74609\" namespace=\"/drugs/lenograstim/powder-and-solvent-for-solution-for-injection\" title=\"Powder and solvent for solution for injection\" count=\"1\" rel=\"link\">Powder and solvent for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5950",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/lenograstim",
    "basename": "lenograstim",
    "title": "LENOGRASTIM",
    "vtmid": "327123007",
    "drugClassification": [
        "Granulocyte-colony stimulating factors"
    ],
    "inheritsFromClass": [
        "GRANULOCYTE-COLONY STIMULATING FACTORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Recombinant human granulocyte-colony stimulating factor, rHuG-CSF"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only)",
                        "html": "Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only)"
                    },
                    {
                        "textContent": "Reduction in the duration of neutropenia and associated complications following peripheral stem cells transplantation for non-myeloid malignancy (specialist use only)",
                        "html": "Reduction in the duration of neutropenia and associated complications following peripheral stem cells transplantation for non-myeloid malignancy (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or subcutaneous injection"
                    ],
                    "textContent": "By intravenous infusion or by subcutaneous injection",
                    "html": "By intravenous infusion or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "150 micrograms/m2 daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes.",
                        "html": "<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Reduction in the duration of neutropenia and associated complications following treatment with cytotoxic-induced neutropenia associated with a significant incidence of febrile neutropenia (specialist use only)",
                        "html": "Reduction in the duration of neutropenia and associated complications following treatment with cytotoxic-induced neutropenia associated with a significant incidence of febrile neutropenia (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "150 micrograms/m2 daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion on chemotherapy.",
                        "html": "<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion on chemotherapy.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only)",
                        "html": "Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "10 micrograms/kg daily for 4&#8211;6 days (5&#8211;6 days in healthy donors).",
                        "html": "<p>10&#8239;micrograms/kg daily for 4&#8211;6 days (5&#8211;6 days in healthy donors).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only)",
                        "html": "Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "150 micrograms/m2 daily until neutrophil count stable in acceptable range, to be started 1&#8211;5 days after completion on chemotherapy, for timing of leucopheresis, consult product literature.",
                        "html": "<p>150&#8239;micrograms/m<sup>2</sup> daily until neutrophil count stable in acceptable range, to be started 1&#8211;5 days after completion on chemotherapy, for timing of leucopheresis, consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Mucositis",
                        "html": "Mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "splenic rupture",
                        "html": "splenic rupture",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion(Granocyte ), give intermittently in Sodium chloride 0.9%; initially reconstitute with 1 mL water for injection provided (do not shake vigorously) then dilute with up to 50 mL infusion fluid for each vial of Granocyte-13 or up to 100 mL infusion fluid for Granocyte-34; give over 30 minutes.",
                "html": "<p>For <i>intravenous infusion</i>(<i>Granocyte</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; initially reconstitute with 1&#8239;mL water for injection provided (do not shake vigorously) then dilute with up to 50&#8239;mL infusion fluid for each vial of <i>Granocyte-13</i> or up to 100&#8239;mL infusion fluid for <i>Granocyte-34</i>; give over 30 minutes.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74609",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78575",
                "label": "Neutropenia",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34593",
                "label": "GRANULOCYTE-COLONY STIMULATING FACTORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74609",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}